Impact of a Systematic Social Work Driven Approach on Medical Power of Attorney Documentation, Knowledge, Attitudes, and Beliefs in Participants With Stage I-IV Gynecological Cancers
NCT ID: NCT03037346
Last Updated: 2025-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
731 participants
INTERVENTIONAL
2017-07-17
2024-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
NCT03671226
Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers
NCT05436327
RCT of QPS vs General Information Sheet
NCT03287492
Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients
NCT01031602
Electronic Reporting of Symptoms After Surgery
NCT02700256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To evaluate medical power of attorney documents (MPOAD) completion rate after a systematic social work counseling and education clinical process.
SECONDARY OBJECTIVES:
I. To determine change in medical power of attorney (MPOA)/primary family caregivers' knowledge, attitudes and beliefs about conditions for quality surrogate medical decision-making (MDM).
II. To determine change in MPOA/primary family caregivers' knowledge of patients' values and goals for MDM.
III. Evaluate patients' and MPOA/primary family caregivers' willingness to participate in future advance care planning discussions to discuss patients' values and goals important to MDM.
IV. Evaluate predictors of patient subgroups most likely to respond to the social work counseling and education clinical process.
V. Explore aspects of the Spanish language version of the advance care planning engagement survey to inform future validation studies.
OUTLINE:
Participants (patients and family caregiver/MPOA) complete questionnaires about knowledge, attitudes, and beliefs of MPOAD. Participants without a MPOAD watch a 4-minute educational video about the importance of the role of MPOA.
After completion of intervention, participants are followed up at 3 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Supportive Care (questionnaires, educational video)
Participants (patients and family caregiver/MPOA) complete questionnaires about knowledge, attitudes, and beliefs of MPOAD. Participants without a MPOAD watch a 4-minute educational video about the importance of the role of MPOA.
Questionnaire Administration
Complete questionnaires about MPOAD
Questionnaire Administration
Ancillary studies
Video
Watch educational video
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaire Administration
Complete questionnaires about MPOAD
Questionnaire Administration
Ancillary studies
Video
Watch educational video
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of invasive gynecologic malignancy stages 1-4.
* New patient in the Gynecologic Oncology Center.
* Adequate capacity to understand and complete MPOAD in the opinion of the study investigator or research assistant.
* Able to speak and understand English and/or Spanish.
* Provision of Institutional Review Board (IRB)-approved informed consent.
* Available MPOA or primary family caregiver who consents to study participation.
* FAMILY CAREGIVER/MPOA
* MPOA or if none documented in electronic health record (EHR), primary family caregiver, as designated by the patient.
* Permission to contact provided by patient.
* Adequate capacity to understand and complete study measures in the opinion of the study investigator or research assistant.
* Provision of IRB-approved informed consent.
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Donna S Zhukovsky
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M D Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2018-01745
Identifier Type: REGISTRY
Identifier Source: secondary_id
2016-0704
Identifier Type: OTHER
Identifier Source: secondary_id
2016-0704
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.